CLINICAL TRIAL: RITUXAN/BEAM VS BEXXAR/BEAM FOR DIFFUSE LARGE B CELL NON-HODGKI

临床试验：RITUXAN/BEAM VS BEXXAR/BEAM 用于弥漫性大 B 细胞非 HODGKI

• 批准号: 8166848
• 负责人: EDWARD David BALL
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166848
• 关键词: Acute Myelocytic Leukemia; Cells; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cytogenetics; Diffuse; Funding; Grant; Hematopoietic; Immune; Incidence; Infection; Institution; Mucositis; Recovery; Research; Research Personnel; Resources; Roche brand of rituximab; Secondary Myelodysplastic Syndrome; Source; Time; Transplantation; United States National Institutes of Health; arm; iodine-131-tositumomab; mortality; reconstitution

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to compare PFS between the two transplant arms. Secondary objectives are to compare overall survival, time to progression, CR and PR proportion at Day 100, time to hematopoietic recovery, hematologic function, incidence of infection, maximum mucositis score by Day +21, immune reconstitution, treatment-related mortality, incidence of myelodysplastic syndrome (MDS), secondary acute myelogenous leukemia (AML), or abnormal cytogenetics between the two arms.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目的是比较两个移植臂之间的PFS。次要目标是比较两组患者的总存活率、进展时间、第100天的CR和PR比例、造血恢复时间、血液功能、感染发生率、截至+21天的最大粘膜炎评分、免疫重建、与治疗相关的死亡率、骨髓增生异常综合征(MDS)、继发性急性髓系白血病(AML)或细胞遗传学异常的发生率。